Balanced secretion of anti-CEA x anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikel


  • gt20173

    Forlagets udgivne version, 1 MB, PDF-dokument


    Kasper Mølgaard , Marta Compte, Molecular Immunology Unit. Hospital Universitario Puerta de Hierro, SpanienNatalia Nuñez del Prado Alanes,
  • Seandean Lykke Harwood
  • Laura Sanz, Servicio de Inmunología, Hospital Universitario Puerta de Hierro, Madrid, Spain, Spanien
  • Luis Álvarez-Vallina
Adoptive transfer of genetically engineered human cells secreting bispecific T cell engagers has shown encouraging therapeutic effects in preclinical models of cancer. However, reducing the toxicity and improving the effectiveness of this emerging immunotherapeutic strategy will be critical to its successful application. We have demonstrated that for gene-based bispecific antibody strategies, two-chain diabodies have a better safety profile than single-chain tandem scFvs, because their reduced tendency to form aggregates reduces the risk of inducing antigen-independent T cell activation. Here, we demonstrate that the incorporation of a 2A self-processing peptide derived from foot-and-mouth disease virus conveying co-translational cleavage into a two-chain anti-CD3 x anti-CEA diabody gene enables near-equimolar expression of diabody chains 1 and 2, and thus increases the final amount of assembled diabody. This was found to maximize diabody-mediated T cell activation and cytotoxicity against CEA-positive tumor cells.
TidsskriftGene Therapy
Sider (fra-til)208-214
Antal sider7
StatusUdgivet - 2017

Se relationer på Aarhus Universitet Citationsformater

ID: 107589260